The world is sitting on the cusp of a new era in medicine. In the coming decade, the life science industry is poised to bring forward a whole range of
The world is sitting on the cusp of a new era in medicine. In the coming decade, the life science industry is poised to bring forward a whole range of cell, gene and other advanced therapies that hold the promise of cures for serious conditions for which there is no effective treatment. Advances in AI, cognitive robotics, blockchain and health IoT, meanwhile, offer huge potential to transform the industry. From early diagnosis and prevention to virtual nursing assistants, and the transformation of R&D, no area of the business will remain untouched. Yet the high price tag commanded by advanced treatments means that radically new ways will need to be found to enable patient access and ensure the sustainability of the healthcare system. And there are many challenges to be addressed before the full potential of the digital transformation can be realized. Can we afford the age of biology and high tech? How will the future unfold?
The FT US Healthcare and Life Sciences Summit, now its seventh successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead.